Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia-Reference-Cited by-同舟云学术

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

Published:2021-03-30 Issue:9 Volume:10 Page:2946-2955
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Tsai Hui‐Jen¹²³^ORCID,Hsiao Hui‐Hua³,Hsu Ya‐Ting⁴^ORCID,Liu Yi‐Chang³,Kao Hsiao‐Wen⁵,Liu Ta‐Chih³⁶,Cho Shih‐Feng³,Feng Xiaoxing⁷,Johnston Amanda⁷,Bomalaski John S.⁷,Kuo Ming‐Chung⁵,Chen Tsai‐Yun⁴^ORCID

Affiliation:

1. National Institute of Cancer ResearchNational Health Research Institutes Tainan Taiwan

2. Department of Oncology College of Medicine National Cheng Kung University HospitalNational Cheng Kung University Tainan Taiwan

3. Division of Hematology/Oncology Department of Internal Medicine Kaohsiung Medical University HospitalKaohsiung Medical University Kaohsiung Taiwan

4. Division of Hematology Department of Internal Medicine College of Medicine National Cheng Kung University HospitalNational Cheng Kung University Tainan Taiwan

5. Division of Hematology‐Oncology Department of Internal Medicine Chang Gung Memorial Hospital at Linkou Linkou Taiwan

6. Division of Hematology‐Oncology and Cancer Center Chang Bing Show Chwan Hospital Changhua Taiwan

7. Polaris Pharmaceuticals, IncPolaris Group San Diego CA USA

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3871

Reference49 articles.

1. Acute Myeloid Leukemia

2. Health Promotion Administration Ministry of Health and Welfare. Taiwan.Health promotion administration annual report.2016.http://www.hpa.gov.tw/EngPages/List.aspx?nodeid=1072.

3. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups

4. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial

5. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arginine deprivation enriches lung cancer proteomes with cysteine by inducing arginine-to-cysteine substitutants;Molecular Cell;2024-05

2. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma;JAMA Oncology;2024-04-01

3. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways;Cell Communication and Signaling;2023-09-21

4. Arginine deprivation as a treatment approach targeting cancer cell metabolism and survival: A review of the literature;European Journal of Pharmacology;2023-08

5. Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment;International Journal of Molecular Sciences;2023-06-26